Search research articles
Contact Us
Filters
Showing results (81-90 of 130) with videos related to
Page
of 13
Sort By:
Journal for Immunotherapy of Cancer
|
December 22, 2021
Early disappearance of tumor antigen-reactive T cells from peripheral blood correlates with superior clinical outcomes in melanoma under anti-PD-1 therapy
Jonas Bochem, Henning Zelba, Janine Spreuer, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 1, 2023
Baseline metastatic growth rate is an independent prognostic marker in patients with advanced BRAF V600 mutated melanoma receiving targeted therapy
Nikolaus B Wagner, Max M Lenders, Kathrin Kühl, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
November 26, 2022
Immune checkpoint inhibition and targeted therapy for melanoma: A patient-oriented cross-sectional comparative multicentre study
Alexander Thiem, Pegah Mashhadiakbar, Christiane Cussigh, et al.
The British Journal of Dermatology
|
February 20, 2026
Melanoma of unknown primary shows oncogenic pattern and clinical course of sun-exposed melanoma
Georg Lodde, Jonida Dollani, Wolfgang Galetzka, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
March 22, 2025
Early termination does not negatively impact the outcome of adjuvant immunotherapy in melanoma
Dirk Tomsitz, Elisabeth Livingstone, Carmen Loquai, et al.
Journal for Immunotherapy of Cancer
|
January 25, 2022
Clinical and molecular characteristics associated with response to therapeutic PD-1/PD-L1 inhibition in advanced Merkel cell carcinoma
Ivelina Spassova, Selma Ugurel, Linda Kubat, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 27, 2017
Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition
Markus V Heppt, Lucie Heinzerling, Katharina C Kähler, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 22, 2021
TERT promoter mutations are associated with longer progression-free and overall survival in patients with BRAF-mutant melanoma receiving BRAF and MEK inhibitor therapy
Carl M Thielmann, Johanna Matull, Anne Zaremba, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 18, 2018
Advanced cutaneous squamous cell carcinoma: A retrospective analysis of patient profiles and treatment patterns-Results of a non-interventional study of the DeCOG
Uwe Hillen, Ulrike Leiter, Sylvie Haase, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 11, 2023
Characterisation and outcome of RAC1 mutated melanoma
Georg C Lodde, Philipp Jansen, Rudolf Herbst, et al.
Page
of 13
Search research articles
Search
Showing results (81-90 of 130) with videos related to
Sort By:
Page
of 13
Journal for Immunotherapy of Cancer
|
December 22, 2021
Early disappearance of tumor antigen-reactive T cells from peripheral blood correlates with superior clinical outcomes in melanoma under anti-PD-1 therapy
Jonas Bochem, Henning Zelba, Janine Spreuer, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 1, 2023
Baseline metastatic growth rate is an independent prognostic marker in patients with advanced BRAF V600 mutated melanoma receiving targeted therapy
Nikolaus B Wagner, Max M Lenders, Kathrin Kühl, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
November 26, 2022
Immune checkpoint inhibition and targeted therapy for melanoma: A patient-oriented cross-sectional comparative multicentre study
Alexander Thiem, Pegah Mashhadiakbar, Christiane Cussigh, et al.
The British Journal of Dermatology
|
February 20, 2026
Melanoma of unknown primary shows oncogenic pattern and clinical course of sun-exposed melanoma
Georg Lodde, Jonida Dollani, Wolfgang Galetzka, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
March 22, 2025
Early termination does not negatively impact the outcome of adjuvant immunotherapy in melanoma
Dirk Tomsitz, Elisabeth Livingstone, Carmen Loquai, et al.
Journal for Immunotherapy of Cancer
|
January 25, 2022
Clinical and molecular characteristics associated with response to therapeutic PD-1/PD-L1 inhibition in advanced Merkel cell carcinoma
Ivelina Spassova, Selma Ugurel, Linda Kubat, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 27, 2017
Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition
Markus V Heppt, Lucie Heinzerling, Katharina C Kähler, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 22, 2021
TERT promoter mutations are associated with longer progression-free and overall survival in patients with BRAF-mutant melanoma receiving BRAF and MEK inhibitor therapy
Carl M Thielmann, Johanna Matull, Anne Zaremba, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 18, 2018
Advanced cutaneous squamous cell carcinoma: A retrospective analysis of patient profiles and treatment patterns-Results of a non-interventional study of the DeCOG
Uwe Hillen, Ulrike Leiter, Sylvie Haase, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 11, 2023
Characterisation and outcome of RAC1 mutated melanoma
Georg C Lodde, Philipp Jansen, Rudolf Herbst, et al.
Page
of 13